iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting

NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, today announced that it will present at the Plant-Based Technology Trends Meeting being held in Meireles, Fortaleza, Brazil from December 2-4, 2018. The meeting is sponsored by Bio-Manguinhos/Fiocruz, a unit of the Brazilian Ministry of Health.

Sancha Salgueiro, Ph.D., MBA, a well-known expert and business development executive focussed on plant-made protein technologies and products, will be presenting:

• Transient expression of therapeutic proteins in plants: a flexible platform for fast and affordable biologics manufacturing
  • Date and Time:  December 4, 2018; 10:00 AM BRT
  • Location: Fiocruz-CE Auditorium, Rua São José, s/n. Precabura, Eusébio-CE, Brazil

“I am honored to have this opportunity to highlight the significant product flexibility, time- and cost-savings provided by iBio’s plant-based technology platform and CDMO offering to my fellow researchers and industry participants and, in so doing, help support the development of new business relationships and commercial collaborations for iBio in Brazil and internationally,” said Dr. Salgueiro.

“We are pleased to be invited to present at this international conference focusing on the latest advances and achievements in the field of plant-based biopharmaceutical development and manufacture of recombinant antibodies and vaccines,” said Robert B. Kay, iBio’s Chairman and CEO. “We look forward to continuing our collaborative relationship with Bio-Manguinhos/Fiocruz as it implements its planned, important expansion of capabilities in the plant-based biopharmaceutical field.”

About iBio, Inc.

iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CDMO, LLC in Bryan, Texas.  The facility houses laboratory and pilot-scale operations, as well as large-scale automated hydroponic systems capable of growing over four million plants as "in process inventory" and delivering over 300 kilograms of therapeutic protein pharmaceutical active ingredient per year.  For more information please visit www.ibioinc.com.  

FORWARD-LOOKING STATEMENTS

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact:

Stephen Kilmer
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

Source: iBio, Inc.

Released December 3, 2018